A breakthrough in treatment for kidney disease that is incurable.

Published Date: 05 Apr 2023

According to the most recent results from the PROTECT phase III trial, sparsentan, a novel therapy for IgA nephropathy, significantly lowers proteinuria—abnormal protein levels in the urine—when compared to the currently recommended drug, irbesartan.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Non-Factor Therapies in Hemophilia: Cutting-Edge Approaches to Individualize Care

2.

FDA approves Blenrep for relapsed or refractory multiple myeloma

3.

X-ray and radar technology combined to reduce cancer screening risks

4.

Extended Maintenance with Imatinib Enhances Disease-Free Survival in High-Risk GIST.

5.

Researchers discuss HER2-low and HER2-zero in breast cancer


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot